Literature DB >> 88215

Inosiplex in the treatment of subacute sclerosing panencephalitis.

R Silverberg, T Brenner, O Abramsky.   

Abstract

Six patients with subacute sclerosing panencephalitis were treated with the antiviral agent inosiplex. The clinical condition of four children continued to deteriorate in spite of the treatment, the condition of one remained unchanged, and that of another improved minimally. The effect of inosiplex in these patients is not evident since this group demonstrated a pattern of progression similar to that seen in subacute sclerosing panencephalitis without specific treatment.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 88215     DOI: 10.1001/archneur.1979.00500420084012

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  9 in total

1.  Subacute sclerosing panencephalitis.

Authors: 
Journal:  Br Med J       Date:  1979-11-03

2.  Use of isoprinosine in subacute sclerosing panencephalitis.

Authors:  E McGrath; L Rosenbloom
Journal:  Arch Dis Child       Date:  1980-10       Impact factor: 3.791

3.  Cerebrospinal fluid IgG changes in subacute sclerosing panencephalitis in the various stages of the disease and during isoprinosine therapy.

Authors:  M Poloni; B Rocchelli; G Lanzi; F Rosano Burgio; D Besana
Journal:  Ital J Neurol Sci       Date:  1981-05

Review 4.  Subacute sclerosing panencephalitis.

Authors:  Ravindra Kumar Garg
Journal:  J Neurol       Date:  2008-10-14       Impact factor: 4.849

5.  A placebo-controlled trial of isoprinosine in patients with multiple sclerosis.

Authors:  N M Milligan; D H Miller; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

Review 6.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 7.  Subacute sclerosing panencephalitis: results of the Canadian Paediatric Surveillance Program and review of the literature.

Authors:  Craig Campbell; Simon Levin; Peter Humphreys; Wikke Walop; Renee Brannan
Journal:  BMC Pediatr       Date:  2005-12-15       Impact factor: 2.125

Review 8.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

Review 9.  Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.

Authors:  Jiří Beran; Marián Špajdel; Jiří Slíva
Journal:  Viruses       Date:  2021-11-09       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.